NCT04841369View on ClinicalTrials.gov

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)

PHASE3CompletedINTERVENTIONAL
Enrollment

3,420

Participants

Timeline

Start Date

April 13, 2021

Primary Completion Date

March 30, 2022

Study Completion Date

September 20, 2022

Conditions
Pneumococcal InfectionsStreptococcal InfectionsBacterial Infections
Interventions
BIOLOGICAL

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）

0.5mL,Intramuscular

BIOLOGICAL

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

0.5mL,Intramuscular

Trial Locations (1)

450016

Neihuang Center for Disease Control and Prevention, Anyang

Sponsors
All Listed Sponsors
collaborator

Henan Center for Disease Control and Prevention

OTHER_GOV

lead

CanSino Biologics Inc.

INDUSTRY